Ondansetron 4MG and 8MG

Amendment / Modification

• The closing date for the solicitation has been extended.

• Original closing date: June 29, 2023, 3:00 PM EST

• New closing date: July 13, 2023, 3:00 PM EST

• Solicitation closing date.

• The deadline for proposal submissions has been extended to July 13, 2023, 3:00 PM EST.

• All other terms and conditions of the original solicitation remain unchanged.

Amendment / Modification

• The closing date for the solicitation has been extended.

• The new closing date is June 29, 2023, at 3:00 PM EST.

• The opening/closing date has been modified.

• The proposal submission deadline has been extended to June 29, 2023, at 3:00 PM EST.

Solicitation / RFP / RFQ

This solicitation (SPE2D2-23-R-0007) is for Ondansetron HCL and ODT tablets in various quantities and dosage forms. The Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel, is procuring these pharmaceutical products through its Pharmaceutical Prime Vendor (PPV) program to supply the Department of Defense (DoD), Department of Veterans Affairs (VA), Indian Health Service (IHS), and Bureau of Prisons (BoP).

• The solicitation covers multiple line items for Ondansetron HCL and ODT tablets in 30-count bottles, 500-count bottles, and 30-count unit dose boxes, with dosages of 4MG and 8MG.

• Products must be compatible with automated dispensing units (e.g., Baxter ATC Canisters, OptiFill).

• Unit of use packaging must include a child-proof closure and a bottle with a minimum size of 100cc.

• Bar code labeling at the unit-of-use package level is required, conforming to GS1-128 or HIBCC standards.

• Product information must be registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.

• Therapeutic equivalents will be considered only if they are FDA-approved with a "A" TE Code, unless all drugs in the family group are "B" rated.

• Offerors must have FDA approval (NDA, ANDA, or Biologic License) for the offered drugs by the solicitation closing date.

• Manufacturing facilities must have current acceptable cGMP status with the FDA.

• This is a firm-fixed-price requirements contract.

• The contract will have a one-year base period and four option years, for a maximum term of five years.

• The Contract Price Effective Date shall be no more than 60 calendar days after award.

• The contract performance date shall be 45 calendar days after award.

• Offers must be submitted electronically via DIBBS by June 8, 2023, 3:00 PM EST.

• The evaluation will be based on Lowest Price Technically Acceptable (LPTA).

• Proposals must include a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2).

• Offerors must complete representations and certifications electronically via SAM or provide them with the offer.

• Past performance will be evaluated based on historical sales data, delivered quantities, and points of contact for three relevant contracts within the last three years.

• The acquisition is unrestricted.

• Offerors must provide their Unique Entity Identifier (UEI) and CAGE code.

• The contract awardee will receive payments from the PPV contractors, not directly from the Government.

• Business-to-business agreements with DLA and VA PPV contractors are required.

• A 0.5% cost recovery fee is embedded in contract prices and must be reported quarterly.